My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Sanofi - American Depositary Shares (NQ:SNY)

47.52 +0.19 (+0.40%)

Streaming Delayed Price Updated: 3:45 PM EST, Jan 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

40 41 Next >

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTC - CRKN), Elevation Oncology, Inc. (Nasdaq - ELEV), Sitio Royalties Corp. (NYSE - STR), Vigil Neuroscience, Inc. (Nasdaq - VIGL)

June 09, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season ↗

June 09, 2025

Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.

Via Benzinga

Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio? ↗

June 08, 2025

Via Benzinga

SANOFI-ADR (NASDAQ:SNY) - A Reliable Dividend Stock with Strong Fundamentals ↗

June 05, 2025

Via Chartmill

Price Over Earnings Overview: Sanofi ↗

May 21, 2025

Via Benzinga

Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta ↗

June 06, 2025

Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates.

Via Benzinga

Topics Bankruptcy

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

June 06, 2025

From Pomerantz LLP

Via GlobeNewswire

RFK Jr. Champions 'Medical Freedom' While Curtailing Access, Say Public Health Experts ↗

June 06, 2025

U.S. Health Secretary Robert F. Kennedy Jr. has championed "medical freedom" while simultaneously limiting access to COVID-19 vaccines and restricting food stamp purchases, creating what public health...

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Flowserve Corporation (NYSE – FLS), Streamline Health Solutions, Inc. (Nasdaq – STRM), Sitio Royalties Corp. (NYSE – STR), Vigil Neuroscience, Inc. (Nasdaq – VIGL)

June 04, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response ↗

June 02, 2025

Kymera's KT-621 achieved rapid, deep STAT6 degradation and showed a strong safety profile in Phase 1, with the next trials planned through early 2026.

Via Benzinga

Sanofi To Buy Blueprint Medicines For Up To $9.5B: Retail Sees More Acquisition Offers From European Pharma Companies ↗

June 02, 2025

Sanofi will pay $129 per share in cash at closing, representing a 27% premium to Blueprint’s closing price on Friday of $101.35.

Via Stocktwits

Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals ↗

June 02, 2025

Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved efficacy and safety profile.

Via Benzinga

Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout ↗

June 02, 2025

Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.

Via Benzinga

Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket ↗

June 02, 2025

Via Benzinga

US Stocks Likely To Open Lower After A Solid May: 'TACO' Trade And 'Run It Hot' Optimism 'Are Consensus At This Point,' Says Expert ↗

June 02, 2025

U.S. stock futures fell on Monday after a mixed close on Friday. Futures of major benchmark indices were trading lower in premarket.

Via Benzinga

Campbell's, SAIC And 3 Stocks To Watch Heading Into Monday ↗

June 02, 2025

Via Benzinga

Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May ↗

May 31, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

Regeneron Pharmaceuticals Crashes 12% On A Surprise Sanofi-Tied Failure ↗

May 30, 2025

Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study.

Via Investor's Business Daily

Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data ↗

May 30, 2025

Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not meet its main goal.

Via Benzinga

Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials

May 30, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For 'Healthy' Pregnant Women, Children ↗

May 27, 2025

RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though the official site still shows it listed.

Via Benzinga

Sanofi, VNVC Launch Vaccine Manufacturing Facility In Vietnam, Says Report: Retail’s Positive ↗

May 27, 2025

According to Reuters, operations at the new facility are expected to begin by the end of 2027.

Via Stocktwits

SANOFI-ADR (NASDAQ:SNY) – A Pharmaceutical Stock With Undervalued Potential ↗

May 26, 2025

SANOFI-ADR (SNY) offers strong profitability, an attractive dividend, and undervalued metrics, making it a compelling choice for value investors in the pharmaceutical sector.

Via Chartmill

Analysts Think These Stocks Could More Than Double in Value

May 23, 2025

Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well.

Via MarketBeat

Topics World Trade

Navitas (NASDAQ: NVTS) Surges on NVIDIA Deal – SNYR, VIGL, XAGE Lead $2 Stock Watch Now, More Inside

May 22, 2025

Via AB Newswire

Topics Artificial Intelligence

Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying ↗

May 22, 2025

The company is working on an Alzheimer's treatment that increases the activity of TREM2, a neuroinflammation target.

Via Investor's Business Daily

Vigil Neuroscience Stock Triples Pre-market On Acquisition By Sanofi: Retail Goes Super Bullish ↗

May 22, 2025

Under the terms of the deal, Sanofi will acquire all outstanding common shares of Vigil for $8 per share in cash at closing.

Via Stocktwits

Sanofi Boosts Alzheimer's Pipeline With Vigil Neuroscience Acquisition ↗

May 22, 2025

Sanofi (SNY) to acquire Vigil Neuroscience (VIGL) for $470 million in cash, plus potential $2 per share payout. Acquisition excludes monoclonal antibody program and is expected to be finalized in Q3...

Via Benzinga

Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

May 21, 2025

From Vigil Neuroscience, Inc.

Via GlobeNewswire

Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment ↗

May 19, 2025

Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

40 41 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.